The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Doc - laying the rules and laws :-)
Then trying to spin his ‘ death to the Un vaxed’ :-)
My word, Doc you have no shame, not your fault tho, years of indoctrination by the BBC has played a major part imo!
Grow up and leave it, like adults would be expected to folks.
Move on to more positive expectations:)
This board should not be about taking pot shots at other contributors. Last week, a somewhat unintelligent and immature individual, who occasionally "visits" this board returned, purely to direct a jibe at one of our most respected and informed contributors. He/she also added further vitriol under the guise of a new identity. I had most of his/her nonsense taken down, before berating him/her and subsequently removing my own contribution, because it offended another occasional contributor.
In my opinion, this board, or any other, should not accept comments that are directed at another contributor. It is nothing short of online bullying. Should any of us find the comments of others to be offensive, we have a system in place for reporting those comments to a moderator. I do not resort to that option too often. The other recourse is to filter an individual's comments.
I should add that I retaliated to the jibe of last week's unintelligent individual in a personal way, as he/she had posted merely to offend another contributor. The aforementioned contributor responded in a far better way by subsequently contributing a detailed and very well -researched piece, easily my post of the week, and that of others from the number of recommendations that it received.
I am very much looking forward to seeing how busy this place gets next Thursday.
Ndn71. I guess you tended a mediocre private school because your rambling post suggests your parents wasted their money and were expecting more of you.
Regards
I see Gilead are having success with their own antiviral trials.
The sp has moved from 35p to £1.62ish in the last 18 months...so a good performance. In the last year, its been a roller coaster...however I still think that with approvals we can get to between £10 and £30 per share....depends on how far we get on our journey, prior to takeover!
I suspect when we move to the next phase in the US there will be a rerate to £7.50 to £10...once production is up scaled and more approvals are achieved, the growth will come.
Frustrating as it is, the company is doing all the right tings to add long term value.
All the best folks...
Even better Doc:
Scrip subscriber base - The Scrip readership has grown to over 100,000 worldwide, half of which are in Europe. Scrip is read by managers and executives working across all disciplines in pharmaceutical and biotech companies worldwide.
Nice bit of free PR, media coverage and chance to shoot the breeze with fellow industry movers and shakers. I'm sure RM /SH or whoever attends will use the opportunity wisely.
This is Huge. To be nominated alongside huge global giants.
Kevin, maybe that was a different award - shortlist only announced today.
Nice reminder, think this was mentioned a good while ago.
Good recognition for Synairgen.
Nice find Bermudashorts.
Not sure whether this has already been posted but Synairgen have been shortlisted for this year's Scrip Awards in the Covid-19 pandemic clinical advance of the year category. The others shortlisted in the same category are BioNTech/Pfizer and Modernal for their covid vaccines and also Regeneron for their monoclonal antibodies. Details below.
https://pharmaintelligence.informa.com/events/awards/scrip-awards-2021/shortlist